File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Extra-medullary relapse of leukemia following allogeneic bone marrow transplantation

TitleExtra-medullary relapse of leukemia following allogeneic bone marrow transplantation
Authors
Issue Date1999
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182
Citation
Hematological Oncology, 1999, v. 17 n. 2, p. 45-52 How to Cite?
AbstractThe curative effect of allogeneic bone marrow transplantation (BMT) for acute and chronic leukemia is attributed to the intensive conditioning chemotherapy with or without radiotherapy, as well as an immune-mediated graft versus leukemia (GVL) effect. A different pattern of relapse has been observed after allogeneic BMT for patients with leukemia. Compared with treatment using conventional chemotherapy alone, isolated extra-medullary relapse of disease appears to be seen more commonly after allogeneic BMT. While a full donor's hematopoiesis may be retained, prolonged morphological remission has been observed in the recipient's bone marrow. There appears to be a population of leukemic cells with an affinity to extra-medullary tissues. The failure of the leukemic clone to repopulate the recipient's marrow suggests the presence of a more profound GVL effect in the marrow environment. The optimal treatment for extra-medullary relapse of leukemia following allogeneic BMT remains uncertain. In the case of isolated extra- medullary relapses following BMT, the leukemia may still be responsive to further treatment with chemotherapy and/or radiotherapy. The prognosis is poor in general, but prolonged survival has been observed in some of these patients. With the preservation of donor's hematopoiesis in the recipient's marrow, the use of intensive chemotherapy followed by donor lymphocyte or stem cell re-infusion is a promising option.
Persistent Identifierhttp://hdl.handle.net/10722/162280
ISSN
2015 Impact Factor: 3.494
2015 SCImago Journal Rankings: 0.767
References

 

DC FieldValueLanguage
dc.contributor.authorAu, WYen_US
dc.contributor.authorKwong, YLen_US
dc.contributor.authorLie, AKWen_US
dc.contributor.authorMa, SKen_US
dc.contributor.authorLiang, Ren_US
dc.date.accessioned2012-09-05T05:18:37Z-
dc.date.available2012-09-05T05:18:37Z-
dc.date.issued1999en_US
dc.identifier.citationHematological Oncology, 1999, v. 17 n. 2, p. 45-52en_US
dc.identifier.issn0278-0232en_US
dc.identifier.urihttp://hdl.handle.net/10722/162280-
dc.description.abstractThe curative effect of allogeneic bone marrow transplantation (BMT) for acute and chronic leukemia is attributed to the intensive conditioning chemotherapy with or without radiotherapy, as well as an immune-mediated graft versus leukemia (GVL) effect. A different pattern of relapse has been observed after allogeneic BMT for patients with leukemia. Compared with treatment using conventional chemotherapy alone, isolated extra-medullary relapse of disease appears to be seen more commonly after allogeneic BMT. While a full donor's hematopoiesis may be retained, prolonged morphological remission has been observed in the recipient's bone marrow. There appears to be a population of leukemic cells with an affinity to extra-medullary tissues. The failure of the leukemic clone to repopulate the recipient's marrow suggests the presence of a more profound GVL effect in the marrow environment. The optimal treatment for extra-medullary relapse of leukemia following allogeneic BMT remains uncertain. In the case of isolated extra- medullary relapses following BMT, the leukemia may still be responsive to further treatment with chemotherapy and/or radiotherapy. The prognosis is poor in general, but prolonged survival has been observed in some of these patients. With the preservation of donor's hematopoiesis in the recipient's marrow, the use of intensive chemotherapy followed by donor lymphocyte or stem cell re-infusion is a promising option.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182en_US
dc.relation.ispartofHematological Oncologyen_US
dc.rightsHematological Oncology. Copyright © John Wiley & Sons Ltd.-
dc.subject.meshBone Marrow Transplantationen_US
dc.subject.meshEurope - Epidemiologyen_US
dc.subject.meshHematopoiesis, Extramedullaryen_US
dc.subject.meshHumansen_US
dc.subject.meshIncidenceen_US
dc.subject.meshLeukemia - Therapyen_US
dc.subject.meshRecurrenceen_US
dc.subject.meshTransplantation, Homologousen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleExtra-medullary relapse of leukemia following allogeneic bone marrow transplantationen_US
dc.typeArticleen_US
dc.identifier.emailKwong, YL:ylkwong@hku.hken_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/(SICI)1099-1069(199906)17:2<45::AID-HON641>3.0.CO;2-6en_US
dc.identifier.pmid10521868-
dc.identifier.scopuseid_2-s2.0-0032714242en_US
dc.identifier.hkuros49580-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0032714242&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume17en_US
dc.identifier.issue2en_US
dc.identifier.spage45en_US
dc.identifier.epage52en_US
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridAu, WY=7202383089en_US
dc.identifier.scopusauthoridKwong, YL=7102818954en_US
dc.identifier.scopusauthoridLie, AKW=24284842400en_US
dc.identifier.scopusauthoridMa, SK=9042504200en_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats